A new drug called sotagliflozin is a dual inhibitor of SGLT-1 and SGLT-2, which means it helps limits the body’s absorption of excess glucose through both the intestines and the kidneys. A new study looked at the safety and efficacy of the drug as an add-on to insulin therapy in people with type 1 diabetes, and found the drug showed promise. Read more